These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Intravitreal tissue plasminogen activator, perfluoropropane (C3F8), and ranibizumab or photodynamic therapy for submacular hemorrhage secondary to wet age-related macular degeneration. Papavasileiou E; Steel DH; Liazos E; McHugh D; Jackson TL Retina; 2013 Apr; 33(4):846-53. PubMed ID: 23400079 [TBL] [Abstract][Full Text] [Related]
6. Early treatment of acute submacular haemorrhage secondary to wet AMD using intravitreal tissue plasminogen activator, C3F8, and an anti-VEGF agent. de Silva SR; Bindra MS Eye (Lond); 2016 Jul; 30(7):952-7. PubMed ID: 27080482 [TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage. Treumer F; Roider J; Hillenkamp J Br J Ophthalmol; 2012 May; 96(5):708-13. PubMed ID: 22174095 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of recombinant tissue plasminogen activator and gas versus bevacizumab and gas for subretinal haemorrhage. Mayer WJ; Hakim I; Haritoglou C; Gandorfer A; Ulbig M; Kampik A; Wolf A Acta Ophthalmol; 2013 May; 91(3):274-8. PubMed ID: 21952010 [TBL] [Abstract][Full Text] [Related]
9. Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy and subretinal tissue plasminogen activator. Kimura S; Morizane Y; Hosokawa M; Shiode Y; Kawata T; Doi S; Matoba R; Hosogi M; Fujiwara A; Inoue Y; Shiraga F Am J Ophthalmol; 2015 Apr; 159(4):683-9. PubMed ID: 25555798 [TBL] [Abstract][Full Text] [Related]
10. Subretinal injection of recombinant tissue plasminogen activator for submacular hemorrhage associated with ruptured retinal arterial macroaneurysm. Inoue M; Shiraga F; Shirakata Y; Morizane Y; Kimura S; Hirakata A Graefes Arch Clin Exp Ophthalmol; 2015 Oct; 253(10):1663-9. PubMed ID: 25418034 [TBL] [Abstract][Full Text] [Related]
11. Submacular combination treatment for management of acute, massive submacular hemorrhage in age-related macular degeneration. Shah SP; Hubschman JP; Gonzales CR; Schwartz SD Ophthalmic Surg Lasers Imaging; 2009; 40(3):308-15. PubMed ID: 19485299 [TBL] [Abstract][Full Text] [Related]
12. TISSUE PLASMINOGEN ACTIVATOR FOR SUBFOVEAL HEMORRHAGE DUE TO AGE-RELATED MACULAR DEGENERATION: Comparison of 3 Treatment Modalities. Fassbender JM; Sherman MP; Barr CC; Schaal S Retina; 2016 Oct; 36(10):1860-5. PubMed ID: 26945238 [TBL] [Abstract][Full Text] [Related]
13. Subretinal coapplication of recombinant tissue plasminogen activator and bevacizumab for neovascular age-related macular degeneration with submacular haemorrhage. Treumer F; Klatt C; Roider J; Hillenkamp J Br J Ophthalmol; 2010 Jan; 94(1):48-53. PubMed ID: 19946027 [TBL] [Abstract][Full Text] [Related]
14. Anti-vascular endothelial growth factor monotherapy in the treatment of submacular hemorrhage secondary to polypoidal choroidal vasculopathy. Cho HJ; Koh KM; Kim HS; Lee TG; Kim CG; Kim JW Am J Ophthalmol; 2013 Sep; 156(3):524-531.e1. PubMed ID: 23769197 [TBL] [Abstract][Full Text] [Related]
15. Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage. Klettner A; Grotelüschen S; Treumer F; Roider J; Hillenkamp J Br J Ophthalmol; 2015 Jun; 99(6):864-9. PubMed ID: 25740806 [TBL] [Abstract][Full Text] [Related]
16. Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study. Hatz K; Prünte C Acta Ophthalmol; 2017 Feb; 95(1):e67-e72. PubMed ID: 27009503 [TBL] [Abstract][Full Text] [Related]
17. Vitrectomy for the treatment of submacular hemorrhages from macular degeneration: a comparison of submacular hemorrhage/membrane removal and submacular tissue plasminogen activator-assisted pneumatic displacement. Thompson JT; Sjaarda RN Trans Am Ophthalmol Soc; 2005; 103():98-107; discussion 107. PubMed ID: 17057793 [TBL] [Abstract][Full Text] [Related]
18. Submacular hemorrhage in neovascular age-related macular degeneration: A synthesis of the literature. Stanescu-Segall D; Balta F; Jackson TL Surv Ophthalmol; 2016; 61(1):18-32. PubMed ID: 26212151 [TBL] [Abstract][Full Text] [Related]
19. Subretinal tissue plasminogen activator injection to treat submacular haemorrhage during age-related macular degeneration. Dewilde E; Delaere L; Vaninbroukx I; Van Calster J; Stalmans P Acta Ophthalmol; 2014 Sep; 92(6):e497-8. PubMed ID: 24943231 [No Abstract] [Full Text] [Related]
20. Intravitreal Recombinant Tissue Plasminogen Activator and Sulphur Hexafluoride Gas for Submacular Haemorrhage Displacement in Age-Related Macular Degeneration: Looking behind the Blood. Maggio E; Peroglio Deiro A; Mete M; Sartore M; Polito A; Prigione G; Guerriero M; Pertile G Ophthalmologica; 2020; 243(3):224-235. PubMed ID: 31905361 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]